logo
AI Icon𝛼SK or Search
ENTITY

BioVie (BIVI US)

2
Analysis
Health Care • United States
BioVie Inc. is a clinical stage biotechnology company engaged in the discovery, development and commercialization of therapies targeting life-threatening complications of liver cirrhosis. The Company's initial disease target is ascites a condition impacting people globally. BioVie is based out of the United States.
more
bullish•BioVie
•16 Aug 2026 10:02

IPO Databook: Biovie (BIVI US) - Aug 2026

BioVie Inc. is a clinical-stage company developing innovative drug therapies for neurological, neurodegenerative disorders, and advanced liver...

Logo
Share
bearish•BioVie
•19 Jul 2026 19:00

BioVie (BIVI US): Synthetic Expert Call Transcript (19 Jul 2026)

SUNRISE-PD as the Clinical and Operational Redemption Anchor: The Phase 2 SUNRISE-PD trial (NCT06757010) monotherapy readout in Q3 2026 is the...

Logo
Share
No more insights

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x